Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Financing Activities
Financing cash flows not reported separately.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns positive
Q1 FY2026 other financing activities was $0, compared with -$374K a year earlier. Trailing-twelve-month other financing activities was $272.12M.
Context
- Other financing activities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $68.03M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (500K) USD
- Year-over-year change
- —
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (500K) | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Financing Activities vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1942.8% is the highest of 6, against a peer median of -98.7%.
- Other financing activities amounts to 1360.6% of revenue for MAZE, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $435.48M USD | +1810.6% | — | 43.2% | |
| LTM Mar 2026 | $272.12M USD | +1942.8% | — | 1360.6% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $62.75M USD | — | — | 65.2% |
| LTM Sep 2026 | $11.8M USD | +661.9% | -32.7% | 1.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $1.21M USD | -100.6% | +107.1% | 11.7% |
| FY2025 | €236.98K EUR | -99.7% | — | 5.3% | |
| LTM Mar 2026 | $158.25K USD | -98.7% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MAZE) | — | -98.7% | +37.2% | 8.5% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.